Closing in on Cancer

We are Merus

Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics®, which are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical studies to have similar features as conventional monoclonal antibodies, such as long half-life and low immunogenicity.

Technology Download Merus' Corporate Presentation
The new face of fighting cancer
The new face of fighting cancer
The new face of fighting cancer
The new face of fighting cancer
Meet our

Management Team

Lex Bakker, Ph.D
SVP & Chief Development Officer
John Crowley, C.P.A.
EVP & Chief Financial Officer
John de Kruif, Ph.D
SVP & Chief Technology Officer
Hui Liu, Ph.D
EVP, Chief Business Officer & Head of Merus U.S.
Ton Logtenberg, Ph.D
Chief Executive Officer
Peter B. Silverman, J.D.
EVP & General Counsel
L. Andres Sirulnik, M.D. Ph.D
EVP & Chief Medical Officer
Mark Throsby, Ph.D
EVP & Chief Scientific Officer
Meet our

Board of Directors

Ton Logtenberg, Ph.D
Chief Executive Officer
Russell Greig
Chairman
Mark Iwicki
Member
Len Kanavy
Member
John de Koning, Ph.D
Member
Greg Perry, C.P.A.
Member
Anand Mehra, M.D.
Member
Anne Noordzij
Secretary

Investors & Media

Nasdaq

Investor Relations

For more information and the latest news about Merus N.V., please visit our Investor Relations section by clicking the button below.

[This section of the website is under construction. You will be temporarily re-routed to Merus’ old website.] 

Investors & Media
Stock information
Nasdaq : MRUS (Common Stock)
$14.06
Change : 0.18 1.26%
Volume : 27,436
Market Cap : 318.217M
Data as of November 16, 2018 @ 04:00 pm EST
(Data provided by Nasdaq. Maximum 15 minutes delayed)